The clinical study of FLAG regimen for refractory acute non-lymphocytic leukemia

Objective To study the efficacy and adverse effects of FLAG regimen (include fludara- bine,cytarabine and G-CSF) in the treatment of refractory acute non-lymphocytic leukemia.Methods 23 patients of refractory acute non-lymphocytic leukemia were treated with FLAG regimen.FLAG regimen was consisted of fludarabine(Flu,25～30 mg·m~(-2)·d~(-1),d1～5,vd),cytarabine(Ara-C 0.5～2 g·m~(-2)·d~(-1),d1～5,vd),and G-CSF(300μg·d~(-1),d0～5 or until ANC count≥0.5×10~9/L,sc).The second course was given if complete re- sponse was not achieved.The clinical efficacy evaluation was divided into complete (CR),partial response (PR) and none response (NR).Results Total effective power was 73.91%,and CR rates 65.22 %.The CR rates in one course was 52.17 %,CR rates in de novo refractory patients were 85.71%,and 87.5 % in ad- vanced stage relapsing patients.Conclusion The outcome of FLAG regimen in the treatment of refractory a- cute non-lymphocytic leukemia was promising,especially for de novo refractory and advanced stage relapsing patients.And the adverse effects were acceptable.In a word,the FLAG regimen is an ideal regimen for re- fractory acute non-lymphocytic leukemia.